ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $122 | -42.7% | 22,947 | +2.8% | 0.00% | – |
| Q2 2023 | $213 | -2.3% | 22,325 | +13.0% | 0.00% | – |
| Q1 2023 | $218 | -23.5% | 19,765 | +2.7% | 0.00% | – |
| Q4 2022 | $285 | -100.0% | 19,246 | -89.3% | 0.00% | -100.0% |
| Q3 2022 | $3,427,000 | -64.5% | 179,294 | -60.4% | 0.00% | 0.0% |
| Q2 2022 | $9,655,000 | +11.7% | 453,057 | +1.0% | 0.00% | 0.0% |
| Q1 2022 | $8,642,000 | -49.4% | 448,702 | -45.5% | 0.00% | -50.0% |
| Q4 2021 | $17,073,000 | -12.2% | 823,168 | +1.2% | 0.00% | 0.0% |
| Q3 2021 | $19,439,000 | -23.0% | 813,694 | -12.0% | 0.00% | 0.0% |
| Q2 2021 | $25,242,000 | +32.9% | 924,958 | +40.9% | 0.00% | 0.0% |
| Q1 2021 | $18,990,000 | +156.9% | 656,421 | +149.8% | 0.00% | +100.0% |
| Q4 2020 | $7,392,000 | -74.5% | 262,781 | -73.5% | 0.00% | -66.7% |
| Q3 2020 | $29,037,000 | -10.0% | 991,021 | -7.1% | 0.00% | -25.0% |
| Q2 2020 | $32,252,000 | +10.4% | 1,066,540 | +8.8% | 0.00% | -20.0% |
| Q1 2020 | $29,222,000 | – | 980,614 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8,434,232 | $162,443,000 | 13.84% |
| Bain Capital Life Sciences Investors, LLC | 3,979,292 | $76,641,000 | 7.44% |
| Pivotal bioVenture Partners Investment Advisor LLC | 569,041 | $10,960,000 | 5.19% |
| Logos Global Management LP | 1,500,000 | $28,890,000 | 3.75% |
| Omega Fund Management, LLC | 623,836 | $12,015,000 | 2.46% |
| Orbimed Advisors | 6,073,850 | $116,982,000 | 1.90% |
| MPM BioImpact LLC | 258,500 | $4,979,000 | 1.34% |
| 1492 Capital Management LLC | 75,192 | $1,448,000 | 0.77% |
| SECTORAL ASSET MANAGEMENT INC | 219,136 | $4,221,000 | 0.75% |
| EcoR1 Capital, LLC | 895,503 | $17,247,000 | 0.54% |